Impact of the COVID-19 pandemic on antipsychotic prescribing in individuals with autism, dementia, learning disability, serious mental illness or living in a care home: a federated analysis of 59 million patients' primary care records in situ using OpenSAFELY.
Orla MacdonaldAmelia GreenAlex WalkerHelen CurtisRichard CrokerAndrew BrownBen Butler-ColeColm AndrewsJon MasseyPeter InglesbyCaroline MortonLouis FisherJessica MorleyAmir MehrkarSebastian BaconSimon DavyDavid EvansIain DillinghamTom WardWilliam HulmeChris BatesJonathan CockburnJohn ParryFrank HesterSam HarperShaun O'HanlonAlex EavisRichard JarvisDima AvramovNasreen ParkesIan WoodBen GoldacreBrian MackennaPublished in: BMJ mental health (2023)
We observed a spike in antipsychotic prescribing in the dementia and care home groups, which correlated with lockdowns and was likely due to prescribing of antipsychotics for palliative care. We observed gradual increases in antipsychotic use in dementia and care home patients and decreases in their use in patients with learning disability or autism.
Keyphrases
- primary care
- palliative care
- healthcare
- end stage renal disease
- mental illness
- ejection fraction
- mild cognitive impairment
- chronic kidney disease
- autism spectrum disorder
- multiple sclerosis
- peritoneal dialysis
- cognitive impairment
- quality improvement
- mental health
- adverse drug
- emergency department
- affordable care act
- patient reported
- health insurance